dCas9p65HSF1

dCas9p65HSF1 is a fusion protein engineered for targeted transcriptional activation in gene editing applications. It combines components of the CRISPR-Cas9 system with transcriptional activators to precisely modulate gene expression without inducing double-strand DNA breaks. The construct consists of a catalytically inactive Cas9 (dCas9), which lacks endonuclease activity but retains its DNA-binding capability, fused to two transcriptional activators: p65, a subunit of the NF-κB transcription factor, and HSF1, the human heat shock factor 1. This fusion enables dCas9p65HSF1 to bind specific DNA sequences guided by a single-guide RNA (sgRNA) and recruit the transcriptional machinery to enhance gene expression at the target locus.

The design leverages the strong activating potential of p65 and the heat shock response element-binding activity of HSF1, which together can significantly upregulate gene transcription. This approach is particularly useful in applications requiring precise, localized gene activation, such as correcting loss-of-function mutations, restoring gene expression in disease models, or studying gene function in vivo. Compared to other CRISPR activation systems, dCas9p65HSF1 has demonstrated robust and reproducible activation across various cell types and organisms, making it a versatile tool in synthetic biology and gene therapy research.

Studies have explored its use in activating genes involved in metabolic pathways, immune responses, and developmental processes. However, like other CRISPR-based tools, dCas9p65HSF1 may face challenges such as off-target effects, potential immune responses, and delivery efficiency, which researchers continue to address through optimization of sgRNA design, protein engineering, and delivery methods. Its application remains an active area of investigation, with ongoing efforts to refine its specificity and efficacy for therapeutic and biotechnological applications.